These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29378196)

  • 1. Additive effect of simultaneous continuous administration of degarelix and TAK-448 on LH suppression in a castrated rat model.
    Stalewski J; Hargrove DM; Wolfe M; Kohout TA; Kamal A
    Eur J Pharmacol; 2018 Apr; 824():24-29. PubMed ID: 29378196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic administration of the metastin/kisspeptin analog KISS1-305 or the investigational agent TAK-448 suppresses hypothalamic pituitary gonadal function and depletes plasma testosterone in adult male rats.
    Matsui H; Tanaka A; Yokoyama K; Takatsu Y; Ishikawa K; Asami T; Nishizawa N; Suzuki A; Kumano S; Terada M; Kusaka M; Kitada C; Ohtaki T
    Endocrinology; 2012 Nov; 153(11):5297-308. PubMed ID: 23027808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of chronic subcutaneous administration of an investigational kisspeptin analog, TAK-683, on gonadotropin-releasing hormone pulse generator activity in goats.
    Yamamura T; Wakabayashi Y; Sakamoto K; Matsui H; Kusaka M; Tanaka T; Ohkura S; Okamura H
    Neuroendocrinology; 2014; 100(2-3):250-64. PubMed ID: 25428554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.
    Matsui H; Masaki T; Akinaga Y; Kiba A; Takatsu Y; Nakata D; Tanaka A; Ban J; Matsumoto S; Kumano S; Suzuki A; Ikeda Y; Yamaguchi M; Watanabe T; Ohtaki T; Kusaka M
    Eur J Pharmacol; 2014 Jul; 735():77-85. PubMed ID: 24747751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
    Broqua P; Riviere PJ; Conn PM; Rivier JE; Aubert ML; Junien JL
    J Pharmacol Exp Ther; 2002 Apr; 301(1):95-102. PubMed ID: 11907162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kisspeptin activation of gonadotropin releasing hormone neurons and regulation of KiSS-1 mRNA in the male rat.
    Irwig MS; Fraley GS; Smith JT; Acohido BV; Popa SM; Cunningham MJ; Gottsch ML; Clifton DK; Steiner RA
    Neuroendocrinology; 2004; 80(4):264-72. PubMed ID: 15665556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies.
    MacLean DB; Matsui H; Suri A; Neuwirth R; Colombel M
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1445-53. PubMed ID: 24762108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of pharmacokinetic/efficacy analysis of an investigational kisspeptin analog, TAK-448, in quantitatively evaluating anti-tumor growth effect in the rat VCaP androgen-sensitive prostate cancer model.
    Ishikawa K; Tanaka A; Kogame A; Watanabe T; Tagawa Y; Matsui H
    Eur J Pharmacol; 2018 Jun; 828():126-134. PubMed ID: 29580912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elucidation of the mechanism of suppressed steroidogenesis during androgen deprivation therapy of prostate cancer patients using a mouse model.
    Taniguchi H; Katano T; Nishida K; Kinoshita H; Matsuda T; Ito S
    Andrology; 2016 Sep; 4(5):964-71. PubMed ID: 27230983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degarelix: a new approach for the treatment of prostate cancer.
    Persson BE; Kold Olesen T; Jensen JK
    Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The GnRH Antagonist Degarelix Suppresses Gonadotropin Secretion and Pituitary Sensitivity in Midgestation Sheep Fetuses.
    Amodei R; Jonker SS; Whitler W; Estill CT; Roselli CE
    Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34958103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice.
    Nakata D; Masaki T; Tanaka A; Yoshimatsu M; Akinaga Y; Asada M; Sasada R; Takeyama M; Miwa K; Watanabe T; Kusaka M
    Eur J Pharmacol; 2014 Jan; 723():167-74. PubMed ID: 24333551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of pharmacokinetics/pharmacodynamics and efficacy of one-month depots of TAK-448 and TAK-683, investigational kisspeptin analogs, in male rats and an androgen-dependent prostate cancer model.
    Tanaka A; Nakata D; Masaki T; Kusaka M; Watanabe T; Matsui H
    Eur J Pharmacol; 2018 Mar; 822():138-146. PubMed ID: 29355559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of long-acting GnRH antagonist, degarelix acetate, on plasma insulin-like peptide 3, testosterone and luteinizing hormone concentrations, and scrotal circumference in male goats.
    Hannan MA; Kawate N; Fukami Y; Weerakoon WW; Büllesbach EE; Inaba T; Tamada H
    Theriogenology; 2017 Jan; 88():228-235. PubMed ID: 27793455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of single or repeated intravenous administration of kisspeptin upon dynamic LH secretion in conscious male rats.
    Tovar S; Vázquez MJ; Navarro VM; Fernández-Fernández R; Castellano JM; Vigo E; Roa J; Casanueva FF; Aguilar E; Pinilla L; Dieguez C; Tena-Sempere M
    Endocrinology; 2006 Jun; 147(6):2696-704. PubMed ID: 16513831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.
    Samant MP; Gulyas J; Hong DJ; Croston G; Rivier C; Rivier J
    J Med Chem; 2005 Jul; 48(15):4851-60. PubMed ID: 16033265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.